Laura C. Michaelis

Laura C. Michaelis

Hematology | Oncology
8800 W. Doyne Ave.
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Journal: Leukemia
Published: March 20, 2026

One academic health center's response to a freedom of expression controversy.

One academic health center's response to a freedom of expression controversy.

Journal: Academic medicine : journal of the Association of American Medical Colleges
Published: September 08, 2025

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.

Journal: Leukemia
Published: October 31, 2024

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment.

The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment.

Journal: Blood
Published: July 15, 2024

40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies.

40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies.

Journal: Haematologica
Published: May 30, 2024

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.

A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Journal: Haematologica
Published: January 12, 2024

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.

Journal: Cancers
Published: January 05, 2024

Identifying Credible Sources of Health Information in Social Media: Phase 2-Considerations for Non-Accredited Nonprofit Organizations, For-Profit Entities, and Individual Sources.

Identifying Credible Sources of Health Information in Social Media: Phase 2-Considerations for Non-Accredited Nonprofit Organizations, For-Profit Entities, and Individual Sources.

Journal: NAM perspectives
Published: November 02, 2023

Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?

Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?

Journal: Acta haematologica
Published: September 06, 2023

An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir.

An extensive database analysis demonstrates significant increase in platelet quantity in unselected hospitalized patients following treatment with oseltamivir.

Journal: Haematologica
Published: September 02, 2023

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.

Journal: Leukemia research
Published: March 21, 2023

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Journal: The Lancet. Haematology
Published: March 05, 2023
Showing 1-12 of 59

Last Updated: 09/26/2026